new report look consid us biosimilar uptak sk biopharm list
found formid earli advantag given celltrion
group strong uptak second wave oncolog biosimilar
us return share celltrion inc cti under-perform
celltrion hc cthc neutral outperform
howev cti/cthc increment gain us seem limit
us truxima in-market strength may sustain year-end
posit effect face competit well lack top-
line translat capac constraint us inflectra face neg
impact channel also pois face competit
highlight skew korean healthcar larg cap
technic factor ipo sk biopharm juli bn
institut alloc schedul lift shortsel ban mid-sep
forese resurg competit risk cut tp
cti under-perform cthc
neutral despit revis
ep cti lower cost /cthc in-market strength
upsid risk includ updat programm
revisit us biosimilar dynam advent second
wave biosimilar us oncolog biosimilar led
celltrion group found diverg uptak trend compar
earlier asset celltrion/pf immunolog biosimilar
inflectra thu revisit assumpt celltrion group us
biosimilar factor
in-market momentum truxima
oncolog biosimilar brituxan tailwind recent win
pass-through statu potenti
market sale gener also note emerg
plan bn long-term target annual sale
biosimilar quarterli sale run bn
stronger
risk
upward revis earn miss
risk us/eu truxima us inflectra focu
despit in-market strength truxima us forese
downsid biosimilar given competit mainli us
inflectra immunolog biosimilar bremciad face neg impact
pass-through statu expiri compet
product samsung/merck retain statu
third entri later year per manag comment
expect us inflectra unlik meet celltrion hc target
share presum base volum year-end
current track volum truxima face challeng
us eu prepar third entri
us schedul fda approv
caution street optim earn
compani perspect note street optim celltrion inc
quarter row project opm bbg stand
indic immin jump celltrion hc
may sustain earn momentum see
improv expect weaker remsima sc outlook
label expans delay single-label current top softer us
outlook
factor korean healthcar
highlight skew korean healthcar sector larg cap
samsung biolog cover celltrion inc celltrion
hc aggreg captur sector trade valu among
local foreign institut late use larg
cap good hide place event biotech
ralli howev find anoth larg cap healthcar list juli sk
biopharm could affect fundflow given bn institut
ipo offer compar fact
local foreign
combin net bought bn stock wherea net sold
bn korean healthcar stock year-to-d
prepar profit-tak activ maintain cautiou view
k-biosimilar given hefti valuat street high expect
high-level view consist diverg earn deliveri valuat
trend celltrion inc celltrion hc weaker earn
celltrion inc sustain cap earn momentum
profit-tak activ trigger institut fundflow impact
schedul lift shortsel ban mid-sep
maintain cautiou view cut tp modestli though
acknowledg
immedi downsid mayb protect given
outright short-sel ban sinc mid-mar forese resurg competit
risk key fundament view cut tp celltrion
inc under-perform celltrion
hc neutral valuat despit
revis ep celltrion inc lower cost
celltrion hc in-market strength upsid risk remain
updat programm merger plan
tp
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau pm univers toronto compani mention price
ray certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
price rate histori celltrion healthcar co ltd
signifi initi assumpt coverag
price rate histori celltrion inc
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european exclud turkey rate base stock total return rel analyst coverag univers
charl martineau pm univers toronto consist compani cover analyst within relev sector outperform repres attract neutral less
attract underperform least attract invest opportun latin america turkey asia exclud japan australia
stock rate base stock total return rel averag total return relev countri region benchmark india
bse sensex index prior octob canadian rate base stock absolut total return potenti
current share price rel attract stock total return potenti within analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk
prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
